LMNL [NASD]
Liminal BioSciences Inc.
Index- P/E- EPS (ttm)-1.07 Insider Own64.13% Shs Outstand31.04M Perf Week-12.30%
Market Cap15.25M Forward P/E- EPS next Y-0.23 Insider Trans0.00% Shs Float11.14M Perf Month-35.91%
Income-32.60M PEG- EPS next Q-0.40 Inst Own0.70% Short Float2.98% Perf Quarter-41.18%
Sales0.30M P/S50.84 EPS this Y25.40% Inst Trans-36.55% Short Ratio7.32 Perf Half Y-60.64%
Book/sh0.82 P/B0.61 EPS next Y28.00% ROA21.00% Target Price2.15 Perf Year-88.13%
Cash/sh1.56 P/C0.32 EPS next 5Y- ROE86.50% 52W Range0.37 - 6.30 Perf YTD-54.14%
Dividend- P/FCF- EPS past 5Y61.30% ROI-48.40% 52W High-92.07% Beta1.60
Dividend %- Quick Ratio- Sales past 5Y-47.70% Gross Margin- 52W Low36.88% ATR0.05
Employees48 Current Ratio2.80 Sales Q/Q-16.20% Oper. Margin- RSI (14)26.36 Volatility7.02% 10.68%
OptionableYes Debt/Eq0.69 EPS Q/Q22.20% Profit Margin- Rel Volume0.58 Prev Close0.51
ShortableYes LT Debt/Eq0.44 EarningsMay 10 AMC Payout0.00% Avg Volume45.38K Price0.50
Recom3.00 SMA20-22.11% SMA50-38.17% SMA200-63.73% Volume26,350 Change-1.98%
Jun-24-21Downgrade H.C. Wainwright Buy → Neutral
Jun-02-21Downgrade Piper Sandler Overweight → Neutral $22 → $4.50
Feb-18-21Initiated H.C. Wainwright Buy $11
Dec-21-20Initiated Piper Sandler Overweight $22
May-23-22 08:00AM  
May-13-22 09:55AM  
May-10-22 04:30PM  
04:30PM  
May-09-22 04:05PM  
08:30AM  
Mar-17-22 06:48PM  
06:48PM  
Mar-14-22 08:00AM  
Mar-07-22 04:59PM  
04:59PM  
Feb-16-22 07:15AM  
07:15AM  
Jan-19-22 04:05PM  
04:05PM  
Nov-15-21 05:15PM  
05:15PM  
Nov-04-21 03:01PM  
Oct-15-21 04:54PM  
04:54PM  
Sep-28-21 04:10PM  
04:10PM  
Aug-23-21 10:00AM  
Aug-16-21 04:05PM  
04:05PM  
Aug-09-21 07:30AM  
Aug-02-21 03:01PM  
Jul-09-21 04:00PM  
04:00PM  
Jun-23-21 08:30AM  
08:30AM  
Jun-04-21 04:27PM  
04:27PM  
03:30PM  
03:30PM  
May-28-21 04:30PM  
May-24-21 01:13PM  
May-21-21 04:45PM  
04:45PM  
May-17-21 04:30PM  
04:30PM  
08:30AM  
08:30AM  
May-05-21 03:00PM  
Mar-28-21 12:40AM  
Mar-24-21 04:39PM  
Mar-17-21 08:46AM  
Mar-12-21 12:30PM  
Mar-04-21 12:38PM  
Feb-12-21 09:00AM  
08:30AM  
Feb-11-21 03:10PM  
Jan-27-21 06:00PM  
Jan-21-21 08:30AM  
Jan-12-21 09:00AM  
Dec-15-20 09:20AM  
09:20AM  
Dec-01-20 08:00AM  
Nov-13-20 09:20AM  
Nov-12-20 04:57PM  
04:57PM  
Nov-10-20 06:33PM  
06:33PM  
Nov-08-20 07:01PM  
Nov-06-20 09:26AM  
Nov-05-20 04:35AM  
04:35AM  
Oct-30-20 08:30AM  
08:30AM  
Oct-07-20 09:30AM  
Sep-21-20 08:16AM  
08:16AM  
Sep-09-20 08:00AM  
Sep-08-20 06:00AM  
Sep-01-20 08:36AM  
08:36AM  
Aug-25-20 08:49AM  
Aug-24-20 01:30PM  
10:03AM  
Aug-10-20 05:01PM  
Aug-06-20 05:01PM  
Jul-22-20 07:55AM  
Jul-17-20 08:00AM  
Jul-02-20 11:16AM  
Jun-30-20 05:31PM  
05:31PM  
05:00PM  
05:00PM  
Jun-11-20 05:00PM  
Jun-09-20 03:53PM  
03:53PM  
May-28-20 05:30PM  
May-22-20 07:14AM  
May-13-20 05:00PM  
Mar-23-20 06:30AM  
Mar-22-20 03:23PM  
03:23PM  
Mar-20-20 05:01PM  
05:01PM  
05:00PM  
Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company's lead product candidate is fezagepras (PBI-4050), which has been completed Phase I clinical trial for the treatment of idiopathic pulmonary, liver, cardiac, or skin fibrosis with fezagepras or related derivatives and respiratory diseases. It is also developing antagonist candidate programs, including G-protein coupled receptor 84 and Oxo-eicosanoid receptor 1, which are in preclinical stage. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.